Loading
The enzyme that turns androgens into oestrogen in fat, muscle and breast tissue after the menopause. Aromatase inhibitors remove the oestrogen that drives most breast cancers in post-menopausal women. This dossier gathers the 3 products (1 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Cytochrome P450 enzyme that aromatises the A ring of androgens to form oestrogens; expressed in adipose tissue, muscle, bone, brain and breast tumour stroma.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| HR-positive / HER2-negative breast cancer | about 70% | Share of breast cancers that are hormone receptor-positive, the population aromatase inhibitors treat | cancer.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Withdrawn or failed |
|---|---|---|
| Small molecule 2 | ||
| Steroidal aromatase inactivator, fortnightly intramuscular injection 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer | - | ||
IBIS-II (International Breast Intervention Study II) ISRCTN31488319 | 3 | Positive | Prevention: anastrozole 1 mg daily for five years against placebo in postmenopausal women at increased risk of breast cancer | Breast cancer in 85 of 1,920 on anastrozole against 165 of 1,944 on placebo after a median 131 months, hazard ratio 0.51 (Lancet 2020). | |
| 3 | Active | SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | - | ||
| 3 | Active | A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 Combined With Letrozole/Anastrozole Versus Placebo Combined With Letrozole/Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer | - | ||
| 2 | - | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Aromatase" OR ABSTRACT:"Aromatase" OR TITLE:"CYP19A1" OR ABSTRACT:"CYP19A1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Aromatase (CYP19A1), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/aromatase.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/aromatase.json. Licence CC BY-NC 4.0.